Multiple Sclerosis Progression News Today

Roches Elecsys NfL test is intended to be used as an aid in detection of disease activity in adults with relapsing-remitting multiple sclerosis or secondary progressive multiple sclerosis.

COVID-19 has no impact on disease activity, progression, or cognitive performance in patients with multiple sclerosis.

Smoking has been linked to more rapid MS progression and greater disease severity but new data suggest oral tobacco use tied to slower disease progression.

"Serious infections did not vary by age, and there were too few serious events to identify any age-related trends by specific TEAE," the authors reported.

A new study examined the prevalence of multiple sclerosis in different ethnic and racial groups and found that the disease is becoming more racially diverse.

"We are looking at larger sample sizes to improve the accuracy and generalizability of our model, but we can use it now to inform treatment decisions."

Data from a phase 3 trial suggest high-dose vitamin D does not prevent relapse in patients with RRMS. However, at least one expert suggests the studys exclusion criteria may have been too broad.

Contrary to previous research, a new study suggests fertility treatments pose little risk of MS relapse in women who undergo fertility treatments, suggesting it may be time for new clinical guidance.

New recommendations help clinicians communicate technical information to help patients with multiple sclerosis achieve better understanding and self-care.

The first randomized trial of a disease-modifying therapy in radiological isolated syndrome, the earliest pre-clinical phase of MS, suggests dimethyl fumarate reduced the risk of a first clinical event by 80%.